These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Theoretic and practical considerations on laboratory monitoring of thrombolytic therapy. Conard J; Samama MM Semin Thromb Hemost; 1987 Apr; 13(2):212-22. PubMed ID: 3114887 [No Abstract] [Full Text] [Related]
4. Can a commercial diagnostic ultrasound device accelerate thrombolysis? An in vitro skull model. Pfaffenberger S; Devcic-Kuhar B; Kollmann C; Kastl SP; Kaun C; Speidl WS; Weiss TW; Demyanets S; Ullrich R; Sochor H; Wöber C; Zeitlhofer J; Huber K; Gröschl M; Benes E; Maurer G; Wojta J; Gottsauner-Wolf M Stroke; 2005 Jan; 36(1):124-8. PubMed ID: 15591211 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the thrombolytic effect of tissue-type plasminogen activator with ultrasonic irradiation: in vitro experiment involving assay of the fibrin degradation products from the clot. Kimura M; Iijima S; Kobayashi K; Furuhata H Biol Pharm Bull; 1994 Jan; 17(1):126-30. PubMed ID: 8148800 [TBL] [Abstract][Full Text] [Related]
6. Plasminogen activation and thrombolysis for ischemic stroke. Medcalf RL; Davis SM Int J Stroke; 2012 Jul; 7(5):419-25. PubMed ID: 22463085 [TBL] [Abstract][Full Text] [Related]
8. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase. Szabo S; Letsch R; Ehlers R; Walter T; Kazmaier S; Helber U; Hoffmeister HM Thromb Res; 2002 Apr; 106(2):113-9. PubMed ID: 12182909 [TBL] [Abstract][Full Text] [Related]
9. [Combined thrombolysis by pharmacokinetically different plasminogen activators]. Maksimenko AV Bioorg Khim; 1998 May; 24(5):376-80. PubMed ID: 9661792 [TBL] [Abstract][Full Text] [Related]
10. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138 [TBL] [Abstract][Full Text] [Related]
11. [Thrombolysis in stroke--rush is good but do not forget the pharmacology!]. Andsberg G; Norrving B Lakartidningen; 2013 Feb 20-26; 110(8):423. PubMed ID: 23488443 [No Abstract] [Full Text] [Related]
12. Serine-proteases as plasminogen activators in terms of fibrinolysis. Flemmig M; Melzig MF J Pharm Pharmacol; 2012 Aug; 64(8):1025-39. PubMed ID: 22775207 [TBL] [Abstract][Full Text] [Related]
13. Change in hemostatic markers after recombinant tissue-type plasminogen activator is not associated with the chance of recanalization. Martí-Fàbregas J; Borrell M; Cocho D; Martínez-Ramírez S; Martínez-Corral M; Fontcuberta J; Martí-Vilalta JL Stroke; 2008 Jan; 39(1):234-6. PubMed ID: 18048863 [TBL] [Abstract][Full Text] [Related]
14. Ultrasound energy and the dissolution of thrombus. Polak JF N Engl J Med; 2004 Nov; 351(21):2154-5. PubMed ID: 15548774 [No Abstract] [Full Text] [Related]
15. Clinical recovery from acute ischemic stroke after early reperfusion of the brain with intravenous thrombolysis. Demchuk AM; Felburg RA; Alexandrov AV N Engl J Med; 1999 Mar; 340(11):894-5. PubMed ID: 10084910 [No Abstract] [Full Text] [Related]
16. Therapeutic applications of transcranial ultrasound devices. Alexandrov AV Expert Rev Med Devices; 2007 Jan; 4(1):1-3. PubMed ID: 17187465 [No Abstract] [Full Text] [Related]
17. Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Tanne D; Macko RF; Lin Y; Tilley BC; Levine SR; Stroke; 2006 Jul; 37(7):1798-804. PubMed ID: 16763191 [TBL] [Abstract][Full Text] [Related]
18. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome. Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569 [TBL] [Abstract][Full Text] [Related]